For a long time, as one of the leading causes of death worldwide, cancer is still threatening human health. How to solve the contradiction of "on-target but off-tumor" has always plagued the research and development of anti-cancer targeted drugs.

AuBrak focuses on developing PROTAC small-molecule anti-tumor drugs using tumor-specific E3 ligase as a carrier. This "on-target and on-tumor" feature of new PROTAC can effectively overcome the obstacles of toxic side effects in research and development, thereby greatly improving the quality of life of patients during treatment and recovery, and reducing medical resources.